Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NM-3 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NM-3 | DRUG | - |
Inclusion Criteria: * Adult patients at least 18 years of age. * All patients must have an advanced solid tumor that has failed standard therapy or for which no standard therapy exists. * Histological or cytological diagnosis of a malignant solid tumor. * Measurable or non-measurable disease. * Any...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
NM-3 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy, and it has been evaluated in patients with advanced solid tumors.
NM-3 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug in oncology.
NM-3 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and potential effectiveness in treating neoplasms.
NM-3 has been studied in a Phase 1 clinical trial with the identifier NCT00046696, titled 'A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.' This trial was completed and enrolled 32 participants in the United States.
No alternative names for NM-3 have been disclosed in the available information. The drug is referred to solely as NM-3 in clinical trial records and development documentation.